Akari Therapeutics携手药明合联 加速开发靶向RNA剪接的新型ADC载荷

美股速递
Apr 06

生物医药公司Akari Therapeutics PLC宣布与药明生物旗下子公司药明合联达成重要战略合作。双方将共同推进该公司创新ADC(抗体偶联药物)载荷技术的研发进程,该技术主要针对RNA剪接机制进行精准靶向。此次合作有望为肿瘤治疗领域带来新的突破性疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10